The maintenance of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. can positively influence investor sentiment and potentially drive up the stock price of Inhibikase Therapeutics in the short term. The significant upside potential highlighted by the price target suggests strong confidence in the company's future performance, particularly in its development of treatments for Parkinson's disease and related disorders.